Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study
- PMID: 34929656
- DOI: 10.1016/j.jocn.2021.11.021
Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study
Abstract
Micro riboneucleic acids (miRNAs) may be transcribed after brain injury and be detectable in plasma. This study aimed to assess the discriminative ability of seven miRNAs in plasma to differentiate between patients with mild traumatic brain injury (mTBI) and healthy controls. Changes in miRNA levels over 28 days were compared to changes in self-reported symptom profile. This was a prospective cohort study with longitudinal measurements of miRNA levels and symptom self-report. The Rivermead Post-Concussion Symptom Questionnaire (RPQ) was used to determine symptom severity. Mean normalised expression ratios (NER) of miRNAs at day 0 between mTBI and healthy controls were compared. An analysis of response profiles compared the response over time of miRNA species with RPQ symptom severity. miRNA levels of subjects who were defined to have "recovered" on Day 7 and 28 were compared to "non-recovered" subjects. There were 28 mTBI patients and 30 healthy controls included for analysis. Symptom severity was significantly higher on the day of injury among mTBI subjects (p < 0.001), and miRNA 32-5p levels were also higher (p = 0.009). Change of miRNA levels were similar to RPQ change at Day 7, but significantly different at Day 28. Differences were observed among miRNA levels of recovered subjects. This study demonstrated differences in miRNA levels among mTBI subjects compared to healthy controls and different miRNA levels among those who had recovered compared to those reporting symptoms. The change in profiles of miRNAs was different to symptom severity, suggesting that the two measures reflect different aspects of brain injury and recovery.
Keywords: Biomarkers; Craniocerebral Trauma; Emergency medicine; MicroRNAs; Sports.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mr. Edmond Sorich is the director of Glia Diagnostics. Glia Diagnostics holds an exclusive IP licence agreement associated with miRNA listed in this manuscript. It did not contribute to any funding related to the study.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
